Arbutus Biopharma Corporation ABUS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $179.13M+10,055% | $1.05M-33.2% | $529K-60.5% | $10.74M+522% | $1.76M+15.1% | ||
| $4.12M-54.0% | $5.01M-43.2% | $5.78M-59.5% | $5.5M-64.6% | $8.96M-41.8% | ||
| $5.89M+1.0% | $3.69M-21.7% | $3.04M-32.9% | $3.33M-55.9% | $5.83M+9.8% | ||
| $11K-96.7% | —— | $11K-96.7% | $11K-96.9% | $330K-7.0% | ||
| $0-100% | $303K+219% | $98K-97.3% | $12.4M— | $12.37M— | ||
| $10.22M-62.8% | $6.34M-59.1% | $9.19M-59.7% | $9.25M-60.3% | $27.46M+31.4% | ||
| $10.22M-62.8% | $6.34M-59.1% | $9.19M-59.7% | $9.25M-60.3% | $27.46M+31.4% | ||
| $168.91M+757% | -$5.29M+62.0% | -$8.66M+59.6% | $1.49M+107% | -$25.7M-32.7% | ||
| 94.3%+1,551pp | -503.3%+382pp | -1,636.9%-35.7pp | 13.9%+1,264pp | -1,456.9%-193pp | ||
| $17K-39.3% | $18K-40.0% | $23K-20.7% | $28K-17.6% | $28K-36.4% | ||
| $815K-31.9% | $877K-40.1% | $952K-45.5% | $1.04M-43.0% | $1.2M-22.5% | ||
| $787K-32.9% | $1.53M+9.5% | $917K-46.8% | $1.04M-42.1% | $1.17M-21.2% | ||
| $169.7M+792% | -$3.76M+70.0% | -$7.74M+60.7% | $2.52M+113% | -$24.53M-37.2% | ||
| 94.7%+1,485pp | -357.4%+439pp | -1,463.5%+9.0pp | 23.5%+1,170pp | -1,390.4%-224pp | ||
| $0.87+769% | -$0.01+85.7% | -$0.04+60.0% | $0.01+109% | -$0.13-30.0% | ||
| $0.88+777% | -$0.01+85.7% | -$0.04+60.0% | $0.01+109% | -$0.13-30.0% | ||
| 195.2M+2.4% | 191.6M+3.2% | 191.8M+1.5% | 192.4M+2.3% | 190.7M+8.6% | ||
| 193.8M+1.6% | 191.6M+3.2% | 191.8M+1.5% | 191.6M+1.9% | 190.7M+8.6% | ||
| $209K-30.1% | —— | $268K-22.1% | $260K+23.2% | $299K+66.1% | ||
| —— | -$457.5K-170% | -$457.5K-170% | -$457.5K-170% | -$457.5K-170% | ||
| $169.6M+791% | -$3.73M+70.4% | -$7.68M+60.6% | $2.5M+113% | -$24.56M-37.8% | ||
| -$97K-213% | —— | $58K-73.4% | -$21K-133% | -$31K-162% | ||
| -$11K-375% | $1K+103% | -$12K-340% | $21K+363% | $4K+131% | ||
| $168.91M+757% | -$5.29M+62.0% | -$8.66M+59.6% | $1.49M+107% | -$25.7M-32.7% | ||
| $168.92M+766% | -$5.2M+61.7% | -$8.65M+59.0% | $1.5M+107% | -$25.37M-33.5% | ||
| $168.92M+766% | -$5.2M+61.7% | -$8.65M+59.0% | $1.5M+107% | -$25.37M-33.5% | ||
| 94.3%+1,532pp | -494.7%+369pp | -1,634.8%-58.7pp | 14%+1,244pp | -1,438.2%-197pp | ||
| $168.91M+757% | -$5.29M+62.0% | -$8.66M+59.6% | $1.49M+107% | -$25.7M-32.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arbutus Biopharma Corporation's revenue?
- Arbutus Biopharma Corporation (ABUS) generated $191.4M in revenue over the trailing twelve months, up 2889.9% year over year.
- Is Arbutus Biopharma Corporation profitable?
- Arbutus Biopharma Corporation reported $160.7M in net income over the trailing twelve months, a 84.0% net margin.
- What is Arbutus Biopharma Corporation's earnings per share?
- Arbutus Biopharma Corporation's diluted EPS over the trailing twelve months is $0.83.
- Where does Arbutus Biopharma Corporation's income statement data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
